United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidothol gel is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - diclona gel is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. diclona gel is contraindicated in patients with a known hypersensitivity to diclofenac sodium. diclona gel is contraindicated in patients in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1), lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - diclona patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. diclona patch is contraindicated in patients with a known hypersensitivity to diclofenac sodium. diclona patch is contraindicated in patients in the setting of coronary artery bypass graft (cabg) surgery.

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recomm

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - ketorolac tromethamine (unii: 4eve5946bq) (ketorolac - unii:yzi5105v0l) - ketorolac tromethamine 15 mg in 1 ml - carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ). acute pain in adult patients ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. the total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see warnings, precautions, dosage and administr

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. it can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. other uses may be considered if deemed clinically relevant. lidothol is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.

Australia - English - Department of Health (Therapeutic Goods Administration)

mobilitycare pty ltd - 47965 - multi-terrain sports wheelchair, electric-motor-driven - all terrain wheelchair, powered where appropiate.

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987) - lidocaine hydrochloride anhydrous 10 mg in 1 ml - lidocaine hydrochloride injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type. marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recomm

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 80 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension usp is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congeni

United States - English - NLM (National Library of Medicine)

terrain pharmaceuticals - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension usp is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congeni